HCW Biologics Inc. (HCWB)
| Market Cap | 16.36M +118.1% |
| Revenue (ttm) | 6.59M +356.2% |
| Net Income | -18.12M |
| EPS | -5.71 |
| Shares Out | 6.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 195,715,714 |
| Open | 1.040 |
| Previous Close | 1.060 |
| Day's Range | 1.030 - 3.990 |
| 52-Week Range | 0.250 - 9.330 |
| Beta | 1.14 |
| Analysts | Buy |
| Price Target | 2.00 (-17.7%) |
| Earnings Date | May 14, 2026 |
About HCWB
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for alopecia areata diseases. The company also develops HCW9201, a fusion protein desi... [Read more]
Financial Performance
In 2025, HCW Biologics's revenue was $54,232, a decrease of -97.89% compared to the previous year's $2.57 million. Losses were -$22.30 million, -25.73% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for HCWB stock is "Buy" and the 12-month stock price target is $2.0.
News
Why Is Penny Stock HCW Biologics (HCWB) Up Today?
HCW Biologics stock rallied on Friday alongside a strong earnings report.
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fu...
HCW Biologics discovers HCW11-040 prevents bronchopulmonary dysplasia
HCW Biologics (HCWB) announced that its scientists and academic collaborators at Queen’s University at Kingston, Ontario discovered that HCW11-040, a second-generation, pembrolizumab-based fusion immu...
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
HCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senescent cells
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
MIRAMAR, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion imm...
HCW Biologics to file IND for HCW11-018b in first half of 2027
HCW Biologics (HCWB) announced major development regarding its tetra-valent, second-generation T-Cell Engager Program based on its TRBC platform technology, which was presented at the poster session a...
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immu...
HCW Biologics closes exclusive worldwide license for HCW11-006
HCW Biologics (HCWB) announced the receipt of full payment of the upfront license fee with a value of $7M from its licensee, Beijing Trimmune Biotech. Trimmune is a new operating…
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a transferable equity interest in licensee
HCW Biologics announces positive research results for CAR-T cell therapy
HCW Biologics (HCWB) “announced results of groundbreaking research studies, published in the peer-reviewed, high-impact journal, Science Advances. These studies were led by Harris Goldstein, M.D., pro...
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances
Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer
HCW Biologics regains compliance with continued listing rules for Nasdaq
HCW Biologics (HCWB) reported that, on February 26, 2026, the Nasdaq Hearings Panel of The Nasdaq Stock Market found that the Company regained compliance with all continued listing rules of…
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter
MIRAMAR, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing...
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
MIRAMAR, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovat...
HCW Biologics, WY Biotech close first round of financing for joint venture
HCW Biologics (HCWB) and WY Biotech jointly announced the commencement of an exclusive worldwide license agreement covering the development and commercialization rights for certain in vivo application...
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
HCW Biologics receiving cash fee and co-founder shares in Trimmunevalued at $7.0 million Trimmune will hold exclusive worldwide license for rights to high potential preclinical molecule created with H...
HCW Biologics files to sell 9.52M shares of common stock, warrants
Maxim Group is the exclusive placement agent in connection with this offering.
HCW Biologics files to sell 3.4M shares of common stock for holders
16:51 EST HCW Biologics (HCWB) files to sell 3.4M shares of common stock for holders
HCW Biologics enters $4M warrant inducement
HCW Biologics (HCWB) entered into a warrant inducement agreement with an investor for the immediate exercise of certain outstanding warrants that the Company issued on November 20, 2024 and May…
HCW Biologics announces initiation of FIH trial of HW9302
HCW Biologics (HCWB) announced the first patient was dosed at The Ohio State University Wexner Medical Center for the Company-sponsored, multi-center first-in-human clinical trial to evaluate HCW9302 ...
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 -- cytokine that maintains proper numbers and functions o...
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
MIRAMAR, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...
HCW Biologics announces latest update for tetra-valent ICI Program
HCW Biologics (HCWB) announced the latest updated data for its tetra-valent, second-generation pembrolizumab-based Immune Checkpoint Inhibitor, ICI, Program constructed using the Company’s novel TRBC ...
HCW Biologics announces data presented for TCE Program based on TRBC platform
HCW Biologics (HCWB) announced the data presented for their tetra-valent, second-generation T-Cell Engager, TCE, Program based on their novel TRBC platform technology, at the SITC 40th Annual Meeting,...